Bionik Laboratories Corp.
BNKL · OTC
3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
|---|---|---|---|---|
| Revenue | $1,805 | $1,274 | $1,193 | $2,153 |
| % Growth | 41.7% | 6.7% | -44.6% | – |
| Cost of Goods Sold | $815 | $320 | $270 | $893 |
| Gross Profit | $990 | $953 | $924 | $1,260 |
| % Margin | 54.8% | 74.8% | 77.4% | 58.5% |
| R&D Expenses | $903 | $999 | $1,492 | $3,889 |
| G&A Expenses | $2,930 | $2,807 | $4,570 | $5,981 |
| SG&A Expenses | $4,912 | $4,727 | $5,587 | $8,154 |
| Sales & Mktg Exp. | $1,982 | $1,921 | $1,025 | $2,173 |
| Other Operating Expenses | $0 | $0 | $0 | $381 |
| Operating Expenses | $5,815 | $5,726 | $7,079 | $12,424 |
| Operating Income | -$4,825 | -$4,773 | -$6,155 | -$11,246 |
| % Margin | -267.3% | -374.7% | -515.8% | -522.2% |
| Other Income/Exp. Net | -$121 | -$5,635 | -$7,465 | -$13,771 |
| Pre-Tax Income | -$4,946 | -$10,408 | -$13,620 | -$25,016 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4,946 | -$10,408 | -$13,620 | -$24,935 |
| % Margin | -274% | -817.1% | -1,141.3% | -1,157.9% |
| EPS | -0.72 | -1.78 | -2.66 | -5.6 |
| % Growth | 59.6% | 33.1% | 52.5% | – |
| EPS Diluted | -0.72 | -1.78 | -2.66 | -5.6 |
| Weighted Avg Shares Out | 6,904 | 5,844 | 5,128 | 4,456 |
| Weighted Avg Shares Out Dil | 6,904 | 5,844 | 5,128 | 4,456 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $107 | $825 | $405 | $182 |
| Depreciation & Amortization | $63 | $103 | $190 | $381 |
| EBITDA | -$4,776 | -$9,480 | -$13,025 | -$24,454 |
| % Margin | -264.6% | -744.3% | -1,091.4% | -1,135.6% |